TOKYO, Feb 19 (Reuters) – A Japanese health ministry panel on Thursday endorsed Sumitomo Pharma’s iPS Cell-derived treatment for Parkinson’s disease, the Mainichi Shimbun newspaper said.
The panel also gave its endorsement to Cuorips’s iPS Cell-derived cardiomyocyte patches for the treatment of severe heart failure, the paper said.
(Reporting by Kiyoshi Takenaka; Editing by Emelia Sithole-Matarise)
Brought to you by www.srnnews.com